We are a research-based specialty
biopharma company determined
to give people all over the world a
longer and better life

We are developing the first vaccine
in the world for protection against
diarrhoea caused by ETEC in both
travellers and endemic populations

We distribute a wide range of
specialty biopharma products with
focus on vaccines and immunoglobulins

Scandinavian Biopharma

Welcome to Scandinavian Biopharma,

We are an entrepreneurial company specialised in global vaccine development, manufacturing, registration and commercialization of biopharmaceutical products. Our team has previously successfully developed, manufactured, registered and globally l[...]
Read more

Scandinavian Biopharma

Scandinavian Biopharma reports 27% growth for 2023 and initiates a pre-study ahead of phase III

Scandinavian Biopharma is pleased to announce another year of significant growth. For the full year 2023, the revenue increased by over 33 MSEK, corresponding an organic growth of 27%. The total revenue for 2023 amounted to 154 MSEK. The ETEC[...]
Read more

R&D

Scandinavian Biopharma

A vaccine the world is waiting for: “It can change the lives of many”

Our VP CMC development, Christine Hägglund, has been interviewed in the magazine Life Science Sweden. In the article, you can read about how a small company in Sweden can be so far ahead in vaccines against diarrheal diseases. Read the full[...]
Read more